Analyst Ratings For Bio-Rad Laboratories (NYSE:BIO)
Today, Deutsche Bank AG reiterated its Buy rating on Bio-Rad Laboratories (NYSE:BIO) with a price target of $255.00.
There are 4 buy ratings on the stock.
The current consensus rating on Bio-Rad Laboratories (NYSE:BIO) is Buy (Score: 3.00) with a consensus target price of $240.00 per share, a potential 4.53% upside.
Some recent analyst ratings include
- 9/18/2017-Deutsche Bank AG Reiterated Rating of Buy.
- 7/14/2017-Jefferies Group LLC Reiterated Rating of Buy.
- 7/13/2017-Wells Fargo & Company initiated coverage with a Outperform rating.
- 10/12/2016-CL King initiated coverage with a Buy rating.
Recent Insider Trading Activity For Bio-Rad Laboratories (NYSE:BIO)
Bio-Rad Laboratories (NYSE:BIO) has insider ownership of 28.29% and institutional ownership of 62.84%.
- On 8/11/2017 Michael Crowley, EVP, sold 700 with an average share price of $215.91 per share and the total transaction amounting to $151,137.00. View SEC Filing
- On 3/7/2017 Michael Crowley, EVP, sold 300 with an average share price of $196.13 per share and the total transaction amounting to $58,839.00. View SEC Filing
- On 11/9/2016 James R. Stark, VP, sold 1,299 with an average share price of $171.42 per share and the total transaction amounting to $222,674.58. View SEC Filing
Recent Trading Activity for Bio-Rad Laboratories (NYSE:BIO)
Shares of Bio-Rad Laboratories closed the previous trading session at with shares trading hands.
